Texas Yale Capital Corp. trimmed its stake in Biogen Inc (NASDAQ:BIIB) by 50.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,987 shares of the biotechnology company’s stock after selling 3,987 shares during the period. Texas Yale Capital Corp.’s holdings in Biogen were worth $932,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in BIIB. Northwest Wealth Management LLC grew its holdings in shares of Biogen by 188.9% during the first quarter. Northwest Wealth Management LLC now owns 104 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 68 shares during the last quarter. Resources Investment Advisors Inc. grew its holdings in shares of Biogen by 500.0% during the first quarter. Resources Investment Advisors Inc. now owns 120 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 100 shares during the last quarter. Weaver Consulting Group bought a new stake in shares of Biogen during the first quarter worth $28,000. Private Ocean LLC bought a new stake in shares of Biogen during the first quarter worth $31,000. Finally, Somerset Trust Co grew its holdings in shares of Biogen by 150.0% during the first quarter. Somerset Trust Co now owns 140 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 84 shares during the last quarter. Hedge funds and other institutional investors own 91.79% of the company’s stock.
NASDAQ:BIIB traded down $1.30 during mid-day trading on Tuesday, hitting $233.91. The company had a trading volume of 265,583 shares, compared to its average volume of 1,354,804. Biogen Inc has a fifty-two week low of $216.12 and a fifty-two week high of $358.41. The company has a fifty day moving average price of $235.81. The company has a current ratio of 2.46, a quick ratio of 2.22 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $43.38 billion, a price-to-earnings ratio of 8.93, a P/E/G ratio of 0.89 and a beta of 0.99.
Several analysts have recently commented on the company. Credit Suisse Group assumed coverage on Biogen in a report on Monday, May 20th. They set an “underperform” rating and a $198.00 target price on the stock. Oppenheimer set a $290.00 target price on Biogen and gave the stock a “buy” rating in a report on Sunday, May 5th. Standpoint Research upgraded Biogen from a “hold” rating to a “buy” rating in a report on Wednesday, June 5th. Canaccord Genuity increased their target price on Biogen from $275.00 to $285.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Finally, Citigroup restated a “neutral” rating on shares of Biogen in a report on Thursday, May 23rd. Three investment analysts have rated the stock with a sell rating, twenty-four have given a hold rating and five have issued a buy rating to the company. Biogen presently has a consensus rating of “Hold” and an average target price of $269.74.
Biogen Company Profile
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.
Recommended Story: Why is the LIBOR significant?
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.